Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11

por Sasaki, Yasutsuna, Yoshida, Yasushi, Sudoh, Kenichi, Hakusui, Hideo, Fujii, Hirofumi, Ohtsu, Tomoko, Wakita, Hisashi, Igarashi, Tadahiko, Itoh, Kuniaki
Publicado 1995

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38

por Sasaki, Yasutsuna, Mizuno, Shoichi, Fujii, Hirofumi, Ohtsu, Tomoko, Wakita, Hisashi, Igarashi, Tadahiko, Itoh, Kuniaki, Sekine, Ikuo, Miyata, Yoshinori, Saijo, Nagahiro
Publicado 1995

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR(4.5)):...

por Nishiwaki, Kaichi, Sugimoto, Kei‐ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Tojo, Arinobu, Wakita, Hisashi
Publicado 2020

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

por Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Publicado 2017

Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission

por Kumagai, Takashi, Nakaseko, Chiaki, Nishiwaki, Kaichi, Yoshida, Chikashi, Ohashi, Kazuteru, Takezako, Naoki, Takano, Hina, Kouzai, Yasuji, Murase, Tadashi, Matsue, Kosei, Morita, Satoshi, Sakamoto, Junichi, Wakita, Hisashi, Sakamaki, Hisashi, Inokuchi, Koiti
Publicado 2020

Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undet...

por Nakamura, Ayako, Ohwada, Chikako, Takeuchi, Masahiro, Takeda, Yusuke, Tsukamoto, Shokichi, Mimura, Naoya, Nagisa, Oshima-Hasegawa, Sugita, Yasumasa, Tanaka, Hiroaki, Wakita, Hisashi, Aotsuka, Nobuyuki, Matsue, Kosei, Yokote, Koutaro, Ohara, Osamu, Nakaseko, Chiaki, Sakaida, Emiko
Publicado 2019

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan

por Takahashi, Naoto, Nishiwaki, Kaichi, Nakaseko, Chiaki, Aotsuka, Nobuyuki, Sano, Koji, Ohwada, Chikako, Kuroki, Jun, Kimura, Hideo, Tokuhira, Michihide, Mitani, Kinuko, Fujikawa, Kazuhisa, Iwase, Osamu, Ohishi, Kohshi, Kimura, Fumihiko, Fukuda, Tetsuya, Tanosaki, Sakae, Takahashi, Saori, Kameoka, Yoshihiro, Nishikawa, Hiroyoshi, Wakita, Hisashi
Publicado 2018

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

por Okamoto, Yuji, Hirano, Mitsuhito, Morino, Kai, Kajita, Masashi K., Nakaoka, Shinji, Tsuda, Mayuko, Sugimoto, Kei-ji, Tamaki, Shigehisa, Hisatake, Junichi, Yokoyama, Hisayuki, Igarashi, Tadahiko, Shinagawa, Atsushi, Sugawara, Takeaki, Hara, Satoru, Fujikawa, Kazuhisa, Shimizu, Seiichi, Yujiri, Toshiaki, Wakita, Hisashi, Nishiwaki, Kaichi, Tojo, Arinobu, Aihara, Kazuyuki
Publicado 2022